GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
In October, when GSK agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits | With a $2.2 billion ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
As part of a new series looking at how pharma has responded to the pandemic, Neale Belson, SVP UK & Ireland and general manager for the UK at GSK, tells us that it is “absolutely critical” to ...
Associate Global Pharmaceutical Analyst at GlobalData. She added that GSK may be getting more bang per buck in terms of its R&D investment, with seven drugs in pre-registration phase compared with ...
GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer. Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback